exRNAdisease

Entry Detail

---



General Information

Database ID: exR0270283 RNA Name: hsa-miR-628-5p RNA Type: miRNA Chromosome: chr15 Starnd: - Coordinate: Start Site(bp): 55372991 End Site(bp): 55373012 External Links: hsa-miR-628-5p

Disease Information

Disease Name: Multiple Sclerosis Disease Category: Nervous System Diseases MeSH ID: D009103 Type: Diseases Category/Nervous System Diseases Alias: Sclerosis, Multiple//Sclerosis, Disseminated//Disseminated Sclerosis//MS (Multiple Sclerosis)//Multiple Sclerosis, Acute Fulminating

Expression Detail

GEO ID: GSE140106 Description: Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment Experimental Design: Fingolimod treatment Case Disease Type: Multiple Sclerosis Case Disease SubType: NA Case Sample: Fingolimod treated Multiple Sclerosis Control Sample: Untreated Number of Case: 27 Number of Control: 27 Number of Samples: 54

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AGTRAP chr1 11736084 11754802 + ASF1B chr19 14119512 14136613 - CA12 chr15 63321378 63381846 - CORO2B chr15 68578993 68727806 + MEIS2 chr15 36889204 37101299 - RAB31 chr18 9708275 9862551 + RACGAP1 chr12 49976923 50033136 - ZBTB39 chr12 56998836 57006546 - ZSCAN22 chr19 58326994 58342332 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001550 chr5 167915606 167921655 + hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0000642 chr15 80390757 80415142 + hsa_circ_0001492 chr5 65284462 65290692 + hsa_circ_0000643 chr15 80412669 80415142 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC020978.7 chr16 68224713 68227734 + KCNQ1OT1 chr11 2608328 2699994 - NEAT1 chr11 65422774 65445540 + Display:

Experiment Detail

GEO ID: GSE140106 Sample Source: Blood Source Fraction: Exosome Platform: GPL11154 Method: NGS Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1907 Sample treatment protocol: Exosomes were isolated from 1 mL RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, Australia) treated serum, by size exclusion chromatography (qEV iZONE Science). RNA Extract protocol: Serum exosomes were processed for RNA extraction using the Plasma/Serum Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) according to the manufacturer's protocol. RNA library preparation protocol: Exosome RNA sequencing libraries were then constructed using the NEBNext Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) according to the manufacturer's instructions.

Reference

PMID: 31721043 Title: Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment Author: Ebrahimkhani S, Beadnall HN, Wang C, Suter CM, Barnett MH, Buckland ME, Vafaee F Journal: Mol Neurobiol. 2020 Feb;57(2):1245-1258. Description: we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy.